02/08/2015 22:39:55 Free Membership Login

Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
06/19/20155:08PMTMFWhat Is a Short Squeeze, and How Can it Affect Your Investments?
http://www.fool.com/investing/beginning/2015/06/19/what-is-a-short-squeeze-and-how-can-it-affect-your.aspx?source=eptadnlnk0000002 More...>>
05/16/20159:19AMTMF3 Ways Personalized Medicine Could Completely Transform Your Life
http://www.fool.com/investing/general/2015/05/16/3-ways-personalized-medicine-could-completely-tran.aspx?source=eptadnlnk0000002 More...>>
05/15/20157:05AMGLOBEMyriad Validates Active Surveillance Threshold With Prolaris(R) for Men With Prostate Cancer
SALT LAKE CITY, May 15, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented clinical data for its Prolaris test at the 2015 American Urological Association (AUA) Annual Meeting being held May 15 to 19 in New Orleans, La. The results highlighted and underscored the significant ability of the Prolaris... More...>>
05/13/20155:05PMGLOBEMyriad Showcases Its Pioneering Research at the 2015 ASCO Annual Meeting
SALT LAKE CITY, May 13, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data from 19 clinical studies at the 2015 American Society of Clinical Oncology annual meeting to be held May 29 to June 2, 2015 in Chicago, Ill. Key podium presentations will highlight new prospective research... More...>>
05/07/20157:05AMGLOBEMyriad to Present New Clinical Data on Prolaris(R) at the AUA 2015 Annual Meeting
SALT LAKE CITY, May 7, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present three studies that demonstrate the value of the Prolaris test for physicians and their patients at the 2015 American Urological Association (AUA) Annual Meeting being held May 15 to 19 in New Orleans, La... More...>>
05/06/201510:27AMARNJMP Securities Cuts Myriad Genetics Price Target to $46.00 (MYGN)
http://www.tickerreport.com/banking-finance/503304/jmp-securities-cuts-myriad-genetics-price-target-to-46-00-mygn/?utm_source=ADVFN&utm_medium=banner&utm_campaign=ADVFN More...>>
05/05/20154:05PMGLOBEMyriad Genetics Reports Fiscal Third-Quarter 2015 Financial Results
Total Revenue of $180.0 Million Adjusted Diluted EPS of $0.40 and Diluted EPS of $0.29 myRisk™ Hereditary Cancer Panel Ended Third Quarter at 58 Percent Conversion Myriad Acquires MVZ Clinic to Facilitate Reimbursement in Germany Company Provides Fiscal Fourth-Quarter 2015 Financial Guidance SALT LAKE CITY, May... More...>>
05/03/20156:00AMDJNMyriad Genetics Fights Off Threats From Rivals
By Joseph Walker SALT LAKE CITY-- Myriad Genetics Inc. used a patent-protected monopoly to become one of the most successful and controversial DNA testing companies in the world. Now, nearly two years after the Supreme Court struck down its gene patents, Myriad is fighting to sustain its business model amid growing threats... More...>>
04/22/20157:05AMGLOBEMyriad to Announce Fiscal Third Quarter 2015 Financial Results on May 5, 2015
SALT LAKE CITY, April 22, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal third quarter 2015 and provide a business update following the close of market on Tuesday, May 5, 2015. The Company also will host a conference call at 4:30 p.m. ET... More...>>
04/19/20157:14AMTMF3 Megatrends in Healthcare
http://www.fool.com/investing/general/2015/04/19/3-megatrends-in-healthcare.aspx?source=eptadnlnk0000002 More...>>
04/11/20159:19AMTMFA Possible Glimpse Into the Future: Is a $1 Prostate Cancer Test on the Way?
http://www.fool.com/investing/general/2015/04/11/a-possible-glimpse-into-the-future-is-a-1-prostate.aspx?source=eptadnlnk0000002 More...>>
04/01/20157:05AMGLOBEMyriad and AstraZeneca Expand Research Collaboration on Lynparza
SALT LAKE CITY, April 1, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the expansion of its companion diagnostic collaboration with AstraZeneca. Under the terms of the expanded agreement, Myriad's BRACAnalysis CDx test will be used to prospectively identify which patients with metastatic... More...>>
03/20/20152:05AMONEMyriad Announces Prolaris(R) Test Biopsy Results From EMPATHY-P Study at European Association of Urology Annual Meeting
Prolaris Modifies Risk Assessment for 42 Percent of European Prostate Cancer Patients SALT LAKE CITY and ZURICH, Switzerland, March 20, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer... More...>>
03/20/20152:05AMGLOBEMyriad Announces Prolaris(R) Test Biopsy Results From EMPATHY-P Study at European Association of Urology Annual Meeting
SALT LAKE CITY and ZURICH, Switzerland, March 20, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology... More...>>
03/17/20157:05AMGLOBEMyriad and BioMarin Expand Collaboration to Evaluate myChoice HRD(TM) as a Companion Diagnostic for Talazoparib
SALT LAKE CITY, March 17, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced an expansion of the Company's collaboration with BioMarin Pharmaceutical Inc. Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD™ companion diagnostic test to prospectively identify patients... More...>>
03/05/20157:05AMGLOBEMyriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa(TM) Platform
SALT LAKE CITY, March 5, 2015 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly owned subsidiary of Myriad Genetics, Inc., (Nasdaq:MYGN) today announced the launch of immunoassay services based on the ultrasensitive Simoa™ (single molecule array) platform developed by Quanterix. The Simoa platform enables the accurate measurement... More...>>
03/04/20157:05AMGLOBEMyriad Publishes myPath(TM) Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology
SALT LAKE CITY, March 4, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath™ Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with... More...>>
03/02/20154:05PMGLOBEMyriad Genetics to Present at the Barclays Global Healthcare Conference
SALT LAKE CITY, March 2, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, president of Myriad Genetic Laboratories, is scheduled to present at the Barclays Global Healthcare Conference at 11:15 a.m. Eastern on March 11, 2015, at Loews Miami Beach Hotel in Miami Beach, Florida... More...>>
02/24/20154:05PMGLOBEMyriad Board Approves $200 Million Increase in Share Repurchase Program
SALT LAKE CITY, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its board of directors has approved an additional $200 million authorization for its share repurchase program. As of the end of December 31, 2014, the Company has repurchased almost $1 billion of stock since the inception... More...>>
02/17/20159:10AMPRNUSGeneDx, Inc. and its Parent BioReference Labs Announce Settlement of Their Cancer Gene Testing Patent Dispute with Myriad Gen...
GeneDx, Inc. and its Parent BioReference Labs Announce Settlement of Their Cancer Gene Testing Patent Dispute with Myriad Genetics PR Newswire WASHINGTON, Feb. 17, 2015 WASHINGTON, Feb. 17, 2015 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox P.L.L.C., an intellectual property law firm in Washington, DC, announced... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq mygn150802 22:39